{"paper_id":"2dfee281-a700-45c6-aa11-48f215abd3cf","body_text":"Danazol, also known as Danocrine, is a medicine used to treat endometriosis, fibrocystic breast disease, hereditary angioedema, and other diseases. The masculinizing adverse effects of danazol, such as voice deepening, acne, and excessive hair growth, limit its use. After its discovery in 1963, danazol received FDA approval for medical usage in 1971.\nGonadotropin-releasing hormone analogs, or GnRH analogs, have essentially supplanted danazol in the treatment of endometriosis due to their superior side-effect profiles, particularly their lack of masculinizing side effects. Danazol’s pharmacology is complex, with several modes of action. Direct inhibition of steroidogenesis-related enzymes, direct binding to and occupation of steroid hormone carrier proteins, followed by steroid hormone displacement from these proteins, and direct binding to and activation of sex hormone receptors are a few examples. The medication is categorized as a weak progestogen, weak antigonadotropin, weak...\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nRights and permissions\nCopyright information\n© 2024 Springer Nature Singapore Pte Ltd.\nAbout this entry\nCite this entry\n(2024). Danazol. In: Dictionary of Toxicology. Springer, Singapore. https://doi.org/10.1007/978-981-99-9283-6_663\nDownload citation\nDOI: https://doi.org/10.1007/978-981-99-9283-6_663\nPublished:\nPublisher Name: Springer, Singapore\nPrint ISBN: 978-981-99-9282-9\nOnline ISBN: 978-981-99-9283-6\neBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences","source_license":"CC0","license_restricted":false}